Guardant Health Inc
Cerrado
SectorSanidad
157.41 -0.3
Resumen
Variación precio
24h
Mínimo
156.16
Máximo
158.93
Ingresos | -8.1M -120M |
|---|---|
Ventas | 33M 335M |
BPA | -0.89 |
Margen de beneficios | -35.866 |
Empleados | 2,490 |
EBITDA | -8.1M -109M |
Próximas Ganancias | 28 oct 2026 |
|---|
Capitalización Mercado | 2.4B 22B |
|---|---|
Apertura anterior | 157.71 |
Cierre anterior | 157.41 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
136 / 339 Clasificación en Healthcare
Guardant Health Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Guardant Health Inc previsión
Sentimiento
By Acuity
136 / 339 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Neutral
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Guardant Health Inc
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.